FDA Phone Call Preceded Untitled Letter To Lilly Over Amyvid
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly promised to remove offending images from promotional materials for its imaging product, but the agency followed up with a “notice of violation” letter two months later anyway.